Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Arena Pharmaceuticals, Inc.    ARNA

Delayed Quote. Delayed  - 09/26 07:05:13 pm
1.76 USD   +1.15%
09/01 ARENA PHARMACEU : Pharmaceutics Announces Formation of Beacon Discov..
08/30 INNOVUS PHARMAC : Pharma Appoints Robert Hoffman As EVP And CFO
08/15 ARENA PHARMACEU : Announces Appointment of Vincent Aurentz as Chief ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Arena Pharmaceuticals, Inc. : Five Star Equities Issues New Research Reports on ARNA, DD, KR and VECO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/17/2013 | 03:05pm CEST

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares hit a low of $7.70 Friday before settling to close at $7.78, a decrease of 6.71 percent. The stock traded in between $7.70 to $8.30 on volume of 8.97 million shares traded. Consumer Reports has recently advised their readers to ?skip? Arena?s weight loss drug, Belviq.

Get more information on Arena Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/ARNA

E I Du Pont De Nemours And Co (NYSE: DD) shares hit a low of $52.16 Friday before settling to close at $52.68, a decrease of 2.23 percent. The stock traded in between $52.16 to $53.70 on volume of 11.28 million shares traded. Jefferies Group currently has a ?hold? rating on the stock and has recently raised its price target on the company to $56.00 from $52.00.

Get more information on Du Pont and free access to the in-depth equity report at:
www.FiveStarEquities.com/DD

The Kroger Co. (NYSE: KR) hit a low of $34.67 Friday before settling to close at $34.79, a decrease of 0.77 percent. The stock traded in between $34.67 to $35.25 on volume of 2.46 million shares traded. Argus currently has a ?buy? rating on the stock and has recently raised its price target on the company to $40.00 from $34.00.

Get more information on Kroger and free access to the in-depth equity report at:
www.FiveStarEquities.com/KR

Veeco Instruments Inc. (NASDAQ: VECO) shares hit a low of $37.74 Friday before settling to close at $38.10, a decrease of 3.20 percent. The stock traded in between $37.74 and $39.04 on volume of 559,990 shares traded. UBS has reiterated it ?neutral? view on the company due to pricing pressure pricing pressure Veeco?s metal organic vapor deposition epitaxial systems.

Get more information on Veeco Instruments and free access to the in-depth equity report at:
www.FiveStarEquities.com/VECO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARENA PHARMACEUTICALS, INC
09/09 ARENA PHARMACEUTICALS : Pharmaceutics Announces Formation of Beacon Discovery
09/01 ARENA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Eve..
09/01 ARENA PHARMACEUTICALS : Pharmaceutics Announces Formation of Beacon Discovery
08/30 INNOVUS PHARMACEUTICALS : Pharma Appoints Robert Hoffman As EVP And CFO
08/25 ARENA PHARMACEUTICALS INC : Other Events (form 8-K)
08/18 ARENA PHARMACEUTICALS : Reports Second Quarter 2016 Financial Results and Provid..
08/15 ARENA PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
08/15 ARENA PHARMACEUTICALS : Announces Appointment of Vincent Aurentz as Chief Busine..
08/09 ARENA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
08/08 ARENA PHARMACEUTICALS : reports 2Q loss
More news
Sector news : Biotechnology & Medical Research - NEC
04:45pDJPfizer Throws Out Plan to Split Into Two Companies
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/07 Arena Co-Founder Steps Down To Run Research Company Contracting With Arena
09/01 Orexigen Inks Contrave Deal For Canada - Why Street Reaction Is Muted
08/26 ZAFGEN : Too Cheap To Ignore
08/10 ARENA : New Direction After $27 Million Loss?
08/08 Arena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q2 2016 Results - Earnings C..
Advertisement
Financials ($)
Sales 2016 46,2 M
EBIT 2016 -76,9 M
Net income 2016 -84,5 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 9,17x
Capi. / Sales 2017 9,31x
Capitalization 423 M
More Financials
Chart ARENA PHARMACEUTICALS, INC
Duration : Period :
Arena Pharmaceuticals, Inc Technical Analysis Chart | ARNA | US0400471027 | 4-Traders
Full-screen chart
Technical analysis trends ARENA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 4,50 $
Spread / Average Target 159%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Amit D. Munshi President, Chief Executive Officer & Director
Craig M. Audet SVP-Operations & Head-Global Regulatory Affairs
Kevin R. Lind Chief Financial Officer & Executive Vice President
Donald D. Belcher Independent Director
Tina Susan Nova Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARENA PHARMACEUTICALS,..-8.42%423
INCYTE CORPORATION-17.95%16 728
CELLTRION, INC.--.--%11 664
LONZA GROUP AG13.18%10 059
QUINTILES TRANSNATIONA..15.66%9 453
SEATTLE GENETICS, INC.24.40%7 845
More Results